tiprankstipranks
Bone Biologics Corp. (BBLG)
NASDAQ:BBLG
US Market

Bone Biologics (BBLG) Stock Price & Analysis

24 Followers

BBLG Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.46 - $55.12
Previous Close$2.27
Volume82.08K
Average Volume (3M)98.08K
Market Cap
$2.00M
Enterprise Value-$1.00M
Total Cash (Recent Filing)$3.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)>-0.1
Beta0.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-76.57
Shares Outstanding1,100,489
10 Day Avg. Volume143,152
30 Day Avg. Volume98,084
Standard Deviation0.65
R-Squared0.05
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

BBLG FAQ

What was Bone Biologics Corp.’s price range in the past 12 months?
Bone Biologics Corp. lowest stock price was $1.46 and its highest was $55.12 in the past 12 months.
    What is Bone Biologics Corp.’s market cap?
    Currently, no data Available
    When is Bone Biologics Corp.’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Bone Biologics Corp.’s earnings last quarter?
    Currently, no data Available
    Is Bone Biologics Corp. overvalued?
    According to Wall Street analysts Bone Biologics Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does Bone Biologics Corp. pay dividends?
      Bone Biologics Corp. does not currently pay dividends.
      What is Bone Biologics Corp.’s EPS estimate?
      Bone Biologics Corp.’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Bone Biologics Corp. have?
      Bone Biologics Corp. has 879,176 shares outstanding.
        What happened to Bone Biologics Corp.’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Bone Biologics Corp.?
        Currently, no hedge funds are holding shares in BBLG
        ---

        Bone Biologics Stock Smart Score

        Company Description

        Bone Biologics Corp.

        Bone Biologics Corp. operates as a medical device company, which engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.
        ---

        BBLG Stock 12 Month Forecast

        Average Price Target

        {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"162":"$162","325":"$325","-1":"-$1","80.5":"$80.5","243.5":"$243.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,80.5,162,243.5,325],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2022","6":"Mar<br/>2023","9":"Jun<br/>2023","12":"Aug<br/>2023","25":"Aug<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,10.19076923076923,9.34153846153846,8.492307692307692,7.643076923076922,6.793846153846154,5.944615384615385,5.095384615384615,4.246153846153846,3.396923076923077,2.5476923076923086,1.6984615384615385,0.8492307692307701,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,10.19076923076923,9.34153846153846,8.492307692307692,7.643076923076922,6.793846153846154,5.944615384615385,5.095384615384615,4.246153846153846,3.396923076923077,2.5476923076923086,1.6984615384615385,0.8492307692307701,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,10.19076923076923,9.34153846153846,8.492307692307692,7.643076923076922,6.793846153846154,5.944615384615385,5.095384615384615,4.246153846153846,3.396923076923077,2.5476923076923086,1.6984615384615385,0.8492307692307701,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":324,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":252,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":96,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":67.22,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":50.33,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":70.8,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":76.08,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":62.04,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":58.25,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":44.04,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":44.16,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
        Similar Stocks
        Company
        Price & Change
        Follow
        BioSig Technologies
        BioLife Solutions
        BioCryst
        Brainstorm Cell Therapeutics

        Best Analysts Covering BBLG

        1 Year
        Elemer PirosRodman & Renshaw
        1 Year Success Rate
        0/1 ratings generated profit
        0%
        1 Year Average Return
        -94.40%
        initiated a buy rating 12 months ago
        Copying Elemer Piros's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -94.40% per trade.
        Popular Stocks
        ---
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis